COVID-19

[Mucosal Immunology] Researchers indicated that intraepithelial CD8+ T cells were activated upon infection of intestinal epithelial cells with SARS-CoV-2, providing one possible explanation for gastrointestinal symptoms associated with COVID-19.

[Bonus BioGroup LTD (GlobeNewswire, Inc.)] Bonus BioGroup LTD, has received official approval from the Israeli Ministry of Health to expand its phase II clinical trials for its MesenCure treatment to health centers and hospitals nationwide. MesenCure leverages advances in cell therapy to treat COVID-19 patients suffering from life-threatening pneumonia, acute respiratory distress, and associated complications caused by the immune system’s hyper-inflammatory response to the virus.

[Stem Cell Research & Therapy] Scientists systematically review preclinical studies, explored the effectiveness of mesenchyal stem cells (MSCs) in the treatment of bleomycin-induced pulmonary fibrosis and analyze the potential mechanism, combined with clinical trials of current MSCs for idiopathic pulmonary fibrosis and COVID-19, so as to provide support for clinical research and transformation of MSCs.

[Haematologica] The authors review the interactions between adenoviral vectors and the hemostatic system of possible relevance for the vaccine associated thrombotic thrombocytopenia syndrome, analyze systematically the clinical data on the reported thrombotic complications of adenovirus-based therapeutics, and discuss all the current hypotheses on the mechanisms triggering this novel syndrome.

[Thorax] COVID-19 has different clinical stages, and effective therapy depends on the location and extent of the infection. Scientists provide a background for understanding the progression of the disease throughout the pulmonary epithelium and discuss therapeutic options.

[Cell Reports] Investigators interrogated whether SARS-CoV-2 vaccines could be improved by incorporating nucleocapsid as an antigen.